Optic nerve thinning and neurosensory retinal degeneration in the rTg4510 mouse model of frontotemporal dementia.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
07 01 2019
Historique:
received: 13 12 2018
accepted: 20 12 2018
entrez: 9 1 2019
pubmed: 9 1 2019
medline: 3 4 2020
Statut: epublish

Résumé

Visual impairments, such as difficulties in reading and finding objects, perceiving depth and structure from motion, and impaired stereopsis, have been reported in tauopathy disorders, such as frontotemporal dementia (FTD). These impairments however have been previously attributed to cortical pathologies rather than changes in the neurosensory retina or the optic nerve. Here, we examined tau pathology in the neurosensory retina of the rTg(tauP301L)4510 mouse model of FTD. Optic nerve pathology in mice was also assessed using MRI, and corresponding measurements taken in a cohort of five FTD sufferers and five healthy controls. rTg(tauP301L)4510 mice were imaged (T2-weighted MRI) prior to being terminally anesthetized and eyes and brains removed for immunohistochemical and histological analysis. Central and peripheral retinal labelling of tau and phosphorylated tau (pTau) was quantified and retinal layer thicknesses and cell numbers assessed. MR volumetric changes of specific brain regions and the optic nerve were compared to tau accumulation and cell loss in the visual pathway. In addition, the optic nerves of a cohort of healthy controls and behavioural variant FTD patients, were segmented from T1- and T2-weighted images for volumetric study. Accumulation of tau and pTau were observed in both the central and peripheral retinal ganglion cell (RGC), inner plexiform and inner nuclear layers of the neurosensory retina of rTg(tauP301L)4510 mice. This pathology was associated with reduced nuclear density (- 24.9 ± 3.4%) of the central RGC layer, and a reduced volume (- 19.3 ± 4.6%) and elevated T2 signal (+ 27.1 ± 1.8%) in the optic nerve of the transgenic mice. Significant atrophy of the cortex (containing the visual cortex) was observed but not in other area associated with visual processing, e.g. the lateral geniculate nucleus or superior colliculus. Atrophic changes in optic nerve volume were similarly observed in FTD patients (- 36.6 ± 2.6%). The association between tau-induced changes in the neurosensory retina and reduced optic nerve volume in mice, combined with the observation of optic nerve atrophy in clinical FTD suggests that ophthalmic tau pathology may also exist in the eyes of FTD patients. If tau pathology and neurodegeneration in the retina were to reflect the degree of cortical tau burden, then cost-effective and non-invasive imaging of the neurosensory retina could provide valuable biomarkers in tauopathy. Further work should aim to validate whether these observations are fully translatable to a clinical scenario, which would recommend follow-up retinal and optic nerve examination in FTD.

Identifiants

pubmed: 30616676
doi: 10.1186/s40478-018-0654-6
pii: 10.1186/s40478-018-0654-6
pmc: PMC6322294
doi:

Substances chimiques

Mapt protein, mouse 0
tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4

Subventions

Organisme : Engineering and Physical Sciences Research Council
ID : EP/N034864/1
Pays : International
Organisme : Medical Research Council
ID : MR/J500422/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008525/1
Pays : United Kingdom
Organisme : NIHR Rare Disease Translational Research Collaboration
ID : BRC149/NS/MH
Pays : International
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/E528979/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K026739/1
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Références

Ann Neurol. 1991 Jan;29(1):41-52
pubmed: 1996878
FEBS Lett. 2008 Mar 19;582(6):901-6
pubmed: 18291106
PLoS One. 2014 Jan 27;9(1):e86576
pubmed: 24475148
Prog Retin Eye Res. 2012 Mar;31(2):152-81
pubmed: 22155051
Ophthalmic Res. 2018;59(4):182-192
pubmed: 29621759
Eur J Neurosci. 2008 Jul;28(1):137-47
pubmed: 18662339
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Neuron. 1998 Nov;21(5):955-8
pubmed: 9856453
Acta Neuropathol. 2014 May;127(5):667-83
pubmed: 24531916
Neurology. 2017 Oct 10;89(15):1604-1611
pubmed: 28887373
J Comp Neurol. 2007 Nov 10;505(2):177-89
pubmed: 17853452
Science. 2005 Jul 15;309(5733):476-81
pubmed: 16020737
Jpn J Ophthalmol. 2005 Mar-Apr;49(2):106-8
pubmed: 15838725
Comput Methods Programs Biomed. 2010 Jun;98(3):278-84
pubmed: 19818524
Clin Exp Ophthalmol. 2011 Apr;39(3):279-81
pubmed: 20973903
Med Image Anal. 2013 Aug;17(6):671-84
pubmed: 23510558
Hum Mutat. 2004 Oct;24(4):277-95
pubmed: 15365985
J Neurol. 2015 Dec;262(12):2635-42
pubmed: 26338813
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
PLoS One. 2014 May 07;9(5):e96568
pubmed: 24804737
Ann Neurol. 2004 Sep;56(3):399-406
pubmed: 15349867
J Neurol Neurosurg Psychiatry. 2011 May;82(5):476-86
pubmed: 20971753
Brain. 2011 Sep;134(Pt 9):2565-81
pubmed: 21908872
Front Neuroanat. 2008 Apr 17;2:1
pubmed: 18958199
J Neuropathol Exp Neurol. 2011 Jan;70(1):63-8
pubmed: 21157377
Neuroimage. 2017 Oct 1;159:334-345
pubmed: 28797738
Can J Ophthalmol. 2008 Feb;43(1):53-60
pubmed: 18219347
J Comp Neurol. 2005 Jan 10;481(2):194-209
pubmed: 15562509
J Alzheimers Dis. 2017;56(3):1101-1107
pubmed: 28106555
Magn Reson Med. 2009 Feb;61(2):364-71
pubmed: 19165898
AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1099-109
pubmed: 10871022
Neurobiol Aging. 2014 Jun;35(6):1364-74
pubmed: 24411290
BMJ. 2013 Aug 06;347:f4827
pubmed: 23920254
Gerontologist. 1995 Jun;35(3):370-6
pubmed: 7622089
Neuroimage. 2015 May 1;111:369-78
pubmed: 25700953
Neurobiol Aging. 2011 Mar;32(3):419-33
pubmed: 19356824
Percept Mot Skills. 1996 Dec;83(3 Pt 1):987-95
pubmed: 8961335
J Neurosci Methods. 1997 Mar;72(1):5-14
pubmed: 9128162
J Neurosci. 2016 May 25;36(21):5785-98
pubmed: 27225768
Neurol Clin. 2003 Aug;21(3):709-28
pubmed: 13677819
Optom Vis Sci. 1995 Feb;72(2):83-91
pubmed: 7753532
J Neurosci. 2016 Feb 17;36(7):2086-100
pubmed: 26888921
Mol Vis. 2012;18:2700-10
pubmed: 23170062
Invest Ophthalmol Vis Sci. 2011 Jul 01;52(7):4886-96
pubmed: 21482641
J Biomed Biotechnol. 2006;2006(3):74539
pubmed: 17047313
Brain Res. 1994 Jan 21;634(2):257-65
pubmed: 8131075
PLoS One. 2012;7(4):e34891
pubmed: 22514688
Life Sci. 2015 Mar 1;124:16-23
pubmed: 25592136

Auteurs

Ian F Harrison (IF)

UCL Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6DD, UK. Ian.harrison@ucl.ac.uk.

Rozalind Whitaker (R)

UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.

Pietro Maria Bertelli (PM)

UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Centre for Experimental Medicine, The Queen's University Belfast, Belfast, BT9 7BL, UK.

James M O'Callaghan (JM)

UCL Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6DD, UK.

Lajos Csincsik (L)

UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Centre for Experimental Medicine, The Queen's University Belfast, Belfast, BT9 7BL, UK.

Martina Bocchetta (M)

Dementia Research Centre, UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK.

Da Ma (D)

UCL Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6DD, UK.
School of Engineering Science, Simon Fraser University, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada.

Alice Fisher (A)

Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Zeshan Ahmed (Z)

Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Tracey K Murray (TK)

Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Michael J O'Neill (MJ)

Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

Jonathan D Rohrer (JD)

Dementia Research Centre, UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK.

Mark F Lythgoe (MF)

UCL Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6DD, UK.

Imre Lengyel (I)

UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Centre for Experimental Medicine, The Queen's University Belfast, Belfast, BT9 7BL, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH